GABAA Receptor α6 Antibody

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, causing a hyperpolarization of the membrane through the opening of a Cl− channel associated with the GABA-A receptor (GABA-A-R) subtype. GABA-A-Rs are important therapeutic targets for a range of sedative, anxiolytic, and hypnotic agents and are implicated in several diseases including epilepsy, anxiety, depression, and substance abuse. The GABA-A-R is a multimeric subunit complex. To date six αs, four βs and four γs, plus alternative splicing variants of some of these subunits, have been identified (Olsen and Tobin, 1990; Whiting et al., 1999; Ogris et al., 2004) . Injection in oocytes or mammalian cell lines of cRNA coding for α- and β-subunits results in the expression of functional GABA-A-Rs sensitive to GABA. However, coexpression of a γ-subunit is required for benzodiazepine modulation. The various effects of the benzodiazepines in brain may also be mediated via different α- subunits of the receptor (McKernan et al., 2000; Mehta and Ticku, 1998; Ogris et al., 2004; Pöltl et al., 2003) .

GABA A antibody, GABA A Receptor alphα6 polypeptide antibody, GABA A receptor alphα6 antibody, GABA A receptor subunit alphα6 antibody, GABA subunit A receptor alphα6 antibody, GABA (A) receptor subunit alpha-6 antibody, GABRα6 antibody, GABRA6 antibody, Gamma aminobutyric acid A receptor alphα6 antibody, Gamma aminobutyric acid GABA A receptor alphα6 antibody, Gamma aminobutyric acid receptor subunit alphα6 antibody, Gamma-aminobutyric acid receptor subunit alpha-6 antibody, GBRA6_HUMAN antibody, MGC116903 antibody, MGC116904 antibody